Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Drug-Induced Inotropic Effects in Early Drug Development. Part 2: Designing and Fabricating Microsystems for Assaying Cardiac Contractility With Physiological Relevance Using Human iPSC-Cardiomyocytes.
Saved in:
| Title: | Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Drug-Induced Inotropic Effects in Early Drug Development. Part 2: Designing and Fabricating Microsystems for Assaying Cardiac Contractility With Physiological Relevance Using Human iPSC-Cardiomyocytes. |
|---|---|
| Authors: | Ribeiro AJS; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translation Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States., Guth BD; Department of Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany.; PreClinical Drug Development Platform (PCDDP), North-West University, Potchefstroom, South Africa., Engwall M; Safety Pharmacology and Animal Research Center, Amgen Research, Thousand Oaks, CA, United States., Eldridge S; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Foley CM; Department of Integrative Pharmacology, Integrated Sciences and Technology, AbbVie, North Chicago, IL, United States., Guo L; Laboratory of Investigative Toxicology, Frederick National Laboratory for Cancer Research, Frederick, MD, United States., Gintant G; Department of Integrative Pharmacology, Integrated Sciences and Technology, AbbVie, North Chicago, IL, United States., Koerner J; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translation Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States., Parish ST; Health and Environmental Sciences Institute, Washington, DC, United States., Pierson JB; Health and Environmental Sciences Institute, Washington, DC, United States., Brock M; Department of Safety Assessment, Genentech, South San Francisco, CA, United States., Chaudhary KW; Global Safety Pharmacology, GlaxoSmithKline plc, Collegeville, PA, United States., Kanda Y; Division of Pharmacology, National Institute of Health Sciences, Kanagawa, Japan., Berridge B; National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, NC, United States. |
| Source: | Frontiers in pharmacology [Front Pharmacol] 2019 Aug 29; Vol. 10, pp. 934. Date of Electronic Publication: 2019 Aug 29 (Print Publication: 2019). |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1663-9812 |
|---|---|
| DOI: | 10.3389/fphar.2019.00934 |
